Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 5, 2025.

By India Edwards HealthDay Reporter

WEDNESDAY, Feb. 5, 2025 -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit.

A new study found that a drug in the same class called exenatide, marketed as Byetta, had no effect on slowing the disease or easing its symtoms.

The trial, published Feb. 4 in The Lancet, followed 194 people with Parkinson's disease for 96 weeks.

Patients were randomly assigned to inject either Byetta or a placebo once a week. The results? Disappointing.

"We found no evidence to support exenatide as a disease-modifying treatment for people with Parkinson's disease," researchers wrote.

There was no improvement in symptoms; no slowing of brain degeneration; no benefit on brain scans; no positive effect.

“It’s hugely disappointing,” Dr. Thomas Foltynie of University College London, who led the trial, told The New York Times. “We were expecting we would come through and we would get a positive result.”

For years now, researchers have hoped that GLP-1 drugs, which have revolutionized treatment of diabetes and weight loss, could also protect neurons and slow brain disease.

In fact, early animal lab studies and smaller clinical trials suggested potential benefits, The Times reported.

But this larger study offered no clear evidence that GLP-1 drugs work for Parkinson's.

“This is a sobering moment,” Dr. Michael S. Okun, a Parkinson’s disease expert at the University of Florida and national medical adviser for the Parkinson’s Foundation, told The Times. “This is a really well done study and it came up empty-handed.”

The study could also impact research into GLP-1 drugs for Alzheimer’s disease, as some researchers have been testing whether these medications might help slow cognitive decline.

But Parkinson’s specialists warn that without a clear understanding of how GLP-1 drugs work in the brain, future studies may be just as disappointing.

“I wouldn’t do another study like this unless you learn what is the target,” Dr. David Standaert, a Parkinson’s researcher at the University of Alabama at Birmingham, told The Times. “What is the biochemistry you are trying to change in the brain? How do these drugs work, anyway?”

Sources

  • The New York Times, media report, Feb. 4, 2025
  • The Lancet, Feb. 4, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-02-06 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords